Entera Bio

Entera Bio CROIC

The Cash Return on Invested Capital (CROIC) of Entera Bio (ENTX) as of Oct 8, 2026 is -55.01 %. In the previous year, Cash Return on Invested Capital (CROIC) was -81.67 % — a change of -32.64% (higher).

CROIC

-55.01 %

YoY

-32.64%

Last updated:

Cash Return on Invested Capital (CROIC) of Entera Bio is 2025 -55.01 % . Cash Return on Invested Capital (CROIC) of Entera Bio was 2024 -81.67 % . It decreases by -32.64% higher compared to the previous year.

The Entera Bio CROIC history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

CROIC
Date
CROIC
Jan 1, 2018
-97.51 USD
Jan 1, 2019
-73.33 USD
Jan 1, 2020
-133.59 USD
Jan 1, 2021
-39.71 USD
Jan 1, 2022
-105.92 USD
Jan 1, 2023
-67.99 USD
Jan 1, 2024
-81.67 USD
Jan 1, 2025
-55.01 USD
The Entera Bio CROIC history
YEARCROICYoY
-55.01 %-32.64%
-81.67 %+20.11%
-67.99 %-35.81%
-105.92 %+166.74%
-39.71 %-70.28%
-133.59 %+82.19%
-73.33 %-24.80%
-97.51 %-689.38%
16.54 %-45.29%
30.24 %+50.25%
20.13 %—
Access this data via the Eulerpool API

Entera Bio Stock analysis

What does Entera Bio do? Entera Bio Ltd is an emerging biotechnology company focused on developing oral medications to treat unmet medical needs. The company was founded in 2010 and is headquartered in Jerusalem, Israel. Its history began with the discovery of the "EnteraGam" molecule in the intestinal cells of breastfed infants, which helps them fight infections. This led to the development of EnteraGam for the treatment of various autoimmune diseases. The company's business model is based on developing oral formulations for existing drugs and discovering and developing new molecules. Its focus areas are osteoporosis, hypoparathyroidism, chronic kidney disease, and autoimmune diseases. Entera Bio is divided into three business divisions: the Oral Protein Delivery Platform, the Oral Parathyroid Hormone (PTH) Platform, and the Collagen-based Platform for Wound Healing. Its products include EB611, a candidate for hypoparathyroidism treatment, EB613 for osteoporosis treatment, and EB612 for chronic kidney disease. These products have potential to improve the lives of millions of patients worldwide. Entera Bio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Entera Bio stock

Cash Return on Invested Capital (CROIC) of Entera Bio is -55.01 % in 2025.

Cash Return on Invested Capital (CROIC) of Entera Bio changed from -81.67 % to -55.01 %, representing a -32.64% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Cash Return on Invested Capital (CROIC) Entera Bio since 2006 – with annual values, charts, and detailed analysis.

CROIC measures the cash return generated on invested capital. Unlike ROIC, it uses free cash flow instead of accounting earnings, providing a purer profitability measure.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Return on Invested Capital (CROIC)'s Entera Bio with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Return on Invested Capital (CROIC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Return on Invested Capital (CROIC).

Access this data via the Eulerpool API

Profitability — Entera Bio

All Key Metrics — Entera Bio